3SBio, (FRA:YFK) EBIT per Share : €5.98 (TTM As of Dec. 2016)

View and export this data going back to . Start your Free Trial

What is 3SBio, EBIT per Share?

3SBio,'s EBIT per Share for the six months ended in Dec. 2016 was €3.44. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2016 was €5.98.

During the past 12 months, the average EBIT per Share Growth Rate of 3SBio, was 20.80% per year. During the past 3 years, the average EBIT per Share Growth Rate was -28.30% per year. During the past 5 years, the average EBIT per Share Growth Rate was -19.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for 3SBio,'s EBIT per Share or its related term are showing as below:

FRA:YFK' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 0 Med: -15.65 Max: 38.7
Current: -28.3

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of 3SBio, was 38.70% per year. The lowest was 0.00% per year. And the median was -15.65% per year.

FRA:YFK's 3-Year EBIT Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 3.4 vs FRA:YFK: -28.30

3SBio,'s EBIT for the six months ended in Dec. 2016 was €78.2 Mil.

3SBio, EBIT per Share Historical Data

The historical data trend for 3SBio,'s EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3SBio, EBIT per Share Chart

3SBio, Annual Data

Trend

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec14

Dec15

Dec16

EBIT per Share

Get a 7-Day Free Trial

0.65

0.69

2.25

3.85

6.02

3SBio, Semi-Annual Data
	Jun06	Dec06	Jun07	Dec07	Jun08	Dec08	Jun09	Dec09	Jun10	Dec10	Jun11	Dec11	Jun12	Dec12	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16
EBIT per Share	Get a 7-Day Free Trial															0.83	1.90	1.97	2.54	3.44

3SBio, EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

3SBio,'s EBIT per Share for the fiscal year that ended in Dec. 2016 is calculated as

	EBIT per Share		(A: Dec. 2016 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	136.694	/	22.710
=	6.02

3SBio,'s EBIT per Share for the quarter that ended in Dec. 2016 is calculated as

	EBIT per Share		(Q: Dec. 2016 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	78.189	/	22.735
=	3.44

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2016 adds up the semi-annually data reported by the company within the most recent 12 months, which was €5.98

3SBio, (FRA:YFK) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

3SBio, EBIT per Share Related Terms

Thank you for viewing the detailed overview of 3SBio,'s EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

3SBio, (FRA:YFK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3SBio, Inc. (FRA:YFK) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.3sbio.com

3SBio Inc is engaged in the healthcare sector based in China. It is a pharmaceutical products company and its core activities pertain to developing, manufacturing and marketing biopharmaceuticals. Its portfolio of products comprises of TPIAO and Yisaipu. TPIAO is the only commercialized recombinant human thrombopoietin (rhTPO) product in the world and Yisaipu is a TNF inhibibator product and accounts for the major share in the pharmaceutical industry in China. Most of the company's activities are focused on China while having a minor footprint in a foreign land.

3SBio, (FRA:YFK) Headlines

No Headlines